In a move that could eventually make weight loss drugs cheaper and easier to access, the Food and Drug Administration Monday approved a second generic in the category of medications known as GLP-1s.

Sandoz US to pay USD 265 million in exchange for full release of all claims by the class Resolves all federal antitrust damages for direct purchaser class plaintiffs’ claims in this litigation, if ...

The full background on the Goldman Sachs case can be found in our update from earlier this year, but here are the critical facts and issues. In 2010 the stock price of petitioner Goldman Sachs Group, ...

Sandoz has announced a number of steps to resolve the US Generic Drug Antitrust Class Action Litigation. Following the previously announced settlements with the U.S. Department of Justice in 2020 and ...

A three-judge panel for the US Court of Appeals for the Second Circuit reversed a district court’s class certification in the decade-long Arkansas Teacher Retirement System v. Goldman Sachs Group ...

Generic use has increased over time in Medicare Part D, but substantial variation across plans persists in a number of common classes. Objectives: The use of generics in Medicare Part D generates cost ...